Castration-resistant prostate cancer: from new pathophysiology to new treatment
SS Sridhar, SJ Freedland, ME Gleave, C Higano… - European urology, 2014 - Elsevier
Context Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
SS Sridhar, SJ Freedland, ME Gleave, C Higano… - European Urology, 2014 - infona.pl
Until recently, the only approved agent for metastatic castration-resistant prostate cancer
(mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant advances in …
(mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant advances in …
[引用][C] Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
SS SRIDHAR, SJ FREEDLAND, ME GLEAVE… - European …, 2014 - pascal-francis.inist.fr
Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment CNRS
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search …
[PDF][PDF] Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
SS Sridhar, SJ Freedland, ME Gleave, C Higano… - EUROPEAN …, 2014 - Citeseer
Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment Page 1
Platinum Priority – Collaborative Review – Prostate Cancer Editorial by Andrew J. Armstrong …
Platinum Priority – Collaborative Review – Prostate Cancer Editorial by Andrew J. Armstrong …
Castration-resistant prostate cancer: from new pathophysiology to new treatment
SS Sridhar, SJ Freedland, ME Gleave… - European …, 2014 - pubmed.ncbi.nlm.nih.gov
Context Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
Castration-resistant prostate cancer: from new pathophysiology to new treatment.
SS Sridhar, SJ Freedland, ME Gleave, C Higano… - European …, 2013 - europepmc.org
Objective To summarize the current literature on the management of mCRPC with a
particular focus on novel chemotherapy approaches, hormonal approaches …
particular focus on novel chemotherapy approaches, hormonal approaches …
[PDF][PDF] Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
SS Sridhar, SJ Freedland, ME Gleave… - EUROPEAN …, 2014 - academia.edu
Context: Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
[引用][C] Castration-resistant prostate cancer: from new pathophysiology to new treatment
SS Sridhar, SJ Freedland, ME Gleave, C Higano… - 2014 - repository.ubn.ru.nl
CONTEXT: Until recently, the only approved agent for metastatic castration-resistant prostate
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
cancer (mCRPC) was docetaxel chemotherapy. But over the last 5 years, significant …
[PDF][PDF] Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
SS Sridhar, SJ Freedland, ME Gleave… - EUROPEAN …, 2014 - 155.207.200.17
Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment Page 1
Platinum Priority – Collaborative Review – Prostate Cancer Editorial by Andrew J. Armstrong …
Platinum Priority – Collaborative Review – Prostate Cancer Editorial by Andrew J. Armstrong …
[引用][C] Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
SS Sridhar, SJ Freedland, ME Gleave, C Higano… - European Urology, 2014 - cir.nii.ac.jp